DSM sales, profit rises on higher prices, volumes

DSM sales, profit rises on higher prices, volumes

In Q4, total group sales went up by 16% and stood at €2,417 million

  • By ICN Bureau | February 16, 2022
DSM has delivered strong full year results, including a very good Q4. Company's 2021 sales grew by 14% and stood at €9,204 million and adjusted EBITDA grew by 18% and reached €1,814. Adjusted net profit was up by 21% and stood at €858 million.
In Q4, total group sales went up by 16% and stood at €2,417 million while the adjusted EBITDA rose by13% and reached €440 million.
Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: "2021 was a pivotal year for DSM and our people in which we accelerated our journey towards becoming a fully focused Health, Nutrition & Bioscience company. In line with our purpose-led strategy, we took further significant climate action and set a more aggressive path toward net-zero. We also launched ambitious new food system commitments to target and measure where we can best make a meaningful impact on the health of people and the planet through our core activities.
Both Nutrition and Materials realized strong results, as we continued to successfully navigate dynamic market conditions including global supply chain and logistics disruptions. We started to counter inflationary pressures in the second half of the year with appropriate pricing actions to offset cost increases, of which the first positive effects can be seen in the fourth quarter, with the remainder being effective as of 2022.
We are well positioned going forward, with an exciting innovation portfolio of sustainability-focused solutions with considerable growth potential such as our methane-inhibiting livestock feed additive Bovaer. We have a positive outlook for 2022 in line with our mid-term strategic targets for our Health, Nutrition & Bioscience activities.”
DSM expects its Health, Nutrition & Bioscience activities to deliver a high-single digit Adjusted EBITDA increase. For the Group, it expects a mid-single digit Adjusted EBITDA increase, with a high-single digit Adjusted Net Operating Free Cash Flow increase. This outlook is based on DSM’s expectation of a stable Adjusted EBITDA in Materials following the strong performance in 2021.   

Register Now to Attend NextGen Chemicals & Petrochemicals Summit 2024, 11-12 July 2024, Mumbai

Other Related stories